Patients with chronic heart failure (CHF) are subject to high rates of mortality and morbidity. Consequently, treatment rates in CHF are high. The treatment algorithm for CHF is well established and heavily genericized. Real-world data (RWD) reveals that oral loop diuretics, beta blockers, and ACE inhibitors are the cornerstones of CHF therapy. However, Entresto, the most recent addition to the CHF armamentarium, continues to experience growing patient share. Here we explore drug-prescribing patterns in CHF and reveal the main characteristics of patients receiving the key CHF agents.
Patient Profiler provides disease-specific, patient-level analysis of the key demographic, clinical, and cost-based metrics underlying brand use, all sourced with DRG’s comprehensive RWD repository.
Markets covered: United States
Key drugs covered: Entresto, Corlanor, BiDil, Coreg CR, Toprol XL, Lasix, beta blockers, ACE inhibitors, ARBs, diuretics, nitrates, spironolactone, eplerenone